Using Siponimod to treat Alzheimer's disease
Official title: Repurposing Siponimod for Alzheimer's Disease
Funded at St. Joseph's Hospital and Medical Center · NIH-10671526 · Data updated 2026-11-12
This study is looking at whether Siponimod, a medicine made for multiple sclerosis, can also help people with Alzheimer's by targeting different brain pathways to slow down the disease, and it will keep an eye on how patients' thinking and health change during treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | St. Joseph's Hospital and Medical Center NIH-funded |
| Lab location | 1 site (Phoenix, United States) |
| Project start | August 15, 2021 |
| Project end | July 31, 2027 |
| Funding year | 2023 |
| Award (this year) | $687,290 |
| NIH project number | 5R01AG073212-03 |
| Project ID | NIH-10671526 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are older adults diagnosed with Alzheimer's disease or those showing early signs of cognitive decline.
✕Less likely to help
Patients with other forms of dementia or those who are not diagnosed with Alzheimer's disease may not benefit from this research.
What this research studies
This research investigates the potential of repurposing Siponimod, a medication originally developed for multiple sclerosis, to treat Alzheimer's disease. The approach focuses on targeting multiple molecular pathways involved in Alzheimer's, which may help slow down or alter the disease's progression. By collaborating with Novartis, the study aims to leverage existing knowledge about Siponimod's effects on the brain and immune system. Patients may be monitored for changes in cognitive function and overall health as part of the treatment process.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that may slow the progression of Alzheimer's disease.
How similar studies have gone: Previous research has shown promise in repurposing medications like Siponimod for neurological conditions, indicating potential for success in this novel application.
Where this research is happening
-
St. Joseph's Hospital and Medical Center
Phoenix, United States Active
Researchers
- Principal investigator: Sabbagh, Marwan Noel — St. Joseph's Hospital and Medical Center
- Study coordinator: Sabbagh, Marwan Noel
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.